CSBio CSBio

X
[{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$393.6 million","upfrontCash":"$8.5 million","newsHeadline":"OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"OSE Immunotherapeutics SA"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The collaboration grants Veloxis worldwide rights to develop, manufacture and commercialize FR104, a CD28 antagonist monoclonal antibody fragment, for all transplant indications. OSE Immunotherapeutics retains all rights to develop FR104 in autoimmune diseases.

            Lead Product(s): FR104

            Therapeutic Area: Immunology Product Name: FR104

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Veloxis Pharmaceuticals

            Deal Size: $393.6 million Upfront Cash: $8.5 million

            Deal Type: Collaboration April 26, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The patent covers novel dosing regimen of FR104 in Europe through 2036 for therapeutic applications in autoimmune diseases, inflammatory diseases, transplantation and graft-versus-host disease.

            Lead Product(s): FR104

            Therapeutic Area: Immunology Product Name: FR104

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 12, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY